83056-2
LaboratoryPD-L1 by clone 28-8 [Interpretation] in Tissue by Immune stain Narrative
Definition
This term should be used to report the narrative impression of PD-L1 (CD274) protein expression in tumor cells as determined by immune staining with anti-PD-L1 clone 28-8. Patients with certain cancers, such as non-squamous non small cell lung cancer (NSCLC) or melanoma, whose tumors are positive for PD-L1 by 28-8 may be eligible for anti-programmed death 1 (PD-1) receptor antibody therapy, which effectively prevents the binding of PD-L1 to PD-1. The percentage of viable tumor cells that show partial or complete PD-L1 membrane staining is reported using [LOINC: 83053-9], and the ordinal staining result using [LOINC: 83055-4]. This term was created for, but is not limited in use to, the Dako PD-L1 28-8 pharmDx test kit, which, as of November 2016, is FDA-approved as a companion diagnostic to assess whether patients with certain cancers are eligible for nivolumab therapy.
LOINC 6-Axis Classification
Component
Programmed cell death ligand 1 by clone 28-8
Property
Imp
Time Aspect
Pt
System
Tiss
Scale Type
Nar
Method Type
Immune stain
Details
Class
PATH
Order/Observation
Both
Short Name
PD-L1 by 28-8 Tiss ImStn-Imp
Display Name
PD-L1 by clone 28-8 Immune stain Nar (Tiss) [Interp]
Related Names
Frequently Asked Questions
What is LOINC code 83056-2?
LOINC code 83056-2 identifies "PD-L1 by clone 28-8 [Interpretation] in Tissue by Immune stain Narrative". This term should be used to report the narrative impression of PD-L1 (CD274) protein expression in tumor cells as determined by immune staining with anti-PD-L1 clone 28-8. Patients with certain cancers, such as non-squamous non small cell lung cancer (NSCLC) or melanoma, whose tumors are positive for PD-L1 by 28-8 may be eligible for anti-programmed death 1 (PD-1) receptor antibody therapy, which effectively prevents the binding of PD-L1 to PD-1. The percentage of viable tumor cells that show partial or complete PD-L1 membrane staining is reported using [LOINC: 83053-9], and the ordinal staining result using [LOINC: 83055-4]. This term was created for, but is not limited in use to, the Dako PD-L1 28-8 pharmDx test kit, which, as of November 2016, is FDA-approved as a companion diagnostic to assess whether patients with certain cancers are eligible for nivolumab therapy.
What does 83056-2 measure?
This code measures Programmed cell death ligand 1 by clone 28-8 in Tiss. It belongs to the PATH class in the LOINC classification.
What is LOINC?
LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.